7MM CKD-HPT, HP, and HK market to reach $4b by 2034

However, high expected therapy costs may limit patient access.

The chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) market across the seven major markets (7MM) is expected to reach $4b in 2034 at a compound annual growth rate of 4.4%.

The potential launch of three late-stage pipeline agents will expand pharmacological treatment options, said Kajal Jaddoo, Senior Pharma Analyst at GlobalData.

However, high expected therapy costs may limit patient access due to reimbursement challenges.

Key opinion leaders noted that adherence to phosphate binders remains a concern, primarily due to pill burden and size.

“Potential barriers to growth of the global CKD-HPT, HP, and HK market include the loss of exclusivity of several key branded products that are expected to face patent and data exclusivity expiration, leading to brand erosion due to the emergence of generics,” Jaddoo added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan